Risk for Cancer Increased in Men, Women With T2DM
Standardized incidence ratio highest for prostate cancer for men, nasopharynx cancer for women.
Prostate Cancer
Darolutamide Granted Priority Review Status for nmCRPC
FDA has accepted a New Drug Application and granted Priority Review for darolutamide for the treatment of nonmetastatic castration-resistant prostate cancer.
Enhanced Reimbursement Incentives for Generic Cancer Drugs Found Not to Affect Prescribing Patterns
Critics of the study say they are not surprised by the study’s conclusions, as oncologists make treatment decisions based on best treatment course, not money.
Single-Dose Brachytherapy Effective for Prostate Cancer
Two-year and three-year biochemical progression-free survival rate of 100 percent for low-risk disease.
Prostate Cancer ADT Found to Increase Depression Risk
Men who receive androgen deprivation therapy after radical prostatectomy have a nearly 2-fold increased risk of depression compared with those who receive no post-surgical treatment.
Long-Term PCa Treatment Outcomes Superior With Radiation Plus ADT
Updated findings from a phase 3 study show significantly better 8-year progression-free survival with external beam radiation therapy added to androgen deprivation therapy (ADT) vs ADT alone.
Surgical Protocol Shows Promise as a New Standard of Care for Oncology Surgery
Implementation of the ERAS protocol has a dramatic effect on outcomes for patients undergoing prostate or renal cancer surgery.
Patient Preference-Based Decision Aid Associated With Improved Outcomes in Prostate Cancer
A clinical trial sought to determine if a web-based patient decision making aid could improve satisfaction with care, reduce regrets, and improve alignment of risk category with treatment choice in men with localized prostate cancer.
Low-Dose Aspirin Does Not Cut Death From Prostate Cancer
But during extended exposure periods of at least five years, low-dose aspirin may cut mortality.
Prostate Cancer Mortality Lowest With Radical Prostatectomy
In a study with a follow-up period of 18 years, men treated with any other modality but radical prostatectomy had higher prostate cancer death risks.
